Саркоидоз кожи: клинические варианты и прогностическое значение


Кирдаков Д.Ф., Фомин В.В., Потекаев Н.Н.

ГБОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития РФ, Москва. ГБОУ ВПО РНИМУ им. Н.И. Пирогова, Москва.
Представлены данные об этологии, патогенезе, особенностях течения, клинических проявлениях и лечении саркоидоза кожи; рассматривается его взаимосвязь с системными проявлениями заболевания. Подчеркивается: саркоидоз кожи, как и другие органные проявления этого заболевания, отличается значительным полиморфизмом клинических признаков. Диагноз саркоидоза кожи, всегда требующий морфологического подтверждения с помощью биопсии, диктует необходимость тщательного обследования, направленного на исключение поражения внутригрудных лимфатических узлов, легких, а также других внутренних органов.

Литература


1. Collin B, Rajaratnam R, Lim R, et al. A retrospective analysis of 34 patients with cutaneous sarcoidosis assessed in a dermatology department. Clin Exp Dermatol 2009;35(2)131–34.


2. Коган Е.А., Корнев Б.М., Попова Е.Н. и др. Интерстициальные болезни легких / под. ред. Н.А. Мухина. М., 2007. С. 120–44.


3. Vokurka M, Lecossier D, du Bois RM, et al. Absence of DNA from mycobacteria of the M.tuberculosis complex in sarcoidosis. Am J Respir Crit Care Med 1997;156:1000–03.


4. Goldberg HJ, Fiedler D, Webb A, et al. Sarcoidosis after treatment with interferon-alpha: a case series and review of the literature. Respir Med 2006;100(11):2063–68.


5. Dal Sacco D, Cozzani E, Parodi A, Rebora A. Scar sarcoidosis after hyaluronic acid injection. Int J Dermatol 2005;44(5):411–12.


6. Grunewald J. Genetics of sarcoidosis. Curr Opin Pulm Med 2008;14(5):434–39.


7. Morais A, Alves H, Lima B, et al. HLA class I and II and TNF-alpha gene polymorphisms in sarcoidosis patients. Rev Port Pneumol 2008; 14(6):727–46.


8. Rossman MD, Thompson B, Frederick M, et al. HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet 2003;73:720–35.


9. Berlin M, Fogdell-Hahn A, Olerup O, et al. HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 1997;156:1601–05.


10. Amoli MM, Thomson W, Hajeer AH, et al. HLADRB1 associations in biopsy proven erythema nodosum. J Rheumatol 2001;28(12):2660–62.


11. Amoli MM, Donn RP, Thomson W, et al. Macrophage migration inhibitory factor gene polymorphism is associated with sarcoidosis in biopsy proven erythema nodosum. J Rheumatol 2002;29(8):1671–73.


12. Amoli MM, Lopez-Agreda H, Suarez-Amor O, et al. Endothelial nitric oxide synthase polymorphisms in biopsy-proven erythema nodosum from a defined population. Clin Exp Rheumatol 2007;25(4):624–26.


13. Mrazek F, Holla LI, Hutyrova B, et al. Association of tumour necrosis factor-alpha, lymphotoxinalpha and HLA-DRB1 gene polymorphisms with Lofgren's syndrome in Czech patients with sarcoidosis. Tissue Antigens 2005; 65(2):163–71.


14. Labunski S, Posern G, Ludwig S, et al. Tumour necrosis factor-alpha promoter polymorphism in erythema nodosum. Acta Derm Venereol 2001;81(1):18–21.


15. Sharma S, Ghosh B, Sharma SK. Association of TNF polymorphisms with sarcoidosis, its prognosis and tumour necrosis factor (TNF)alpha levels in Asian Indians. Clin Exp Immunol 2008;151(2):251–59.


16. McDougal KE, Fallin MD, Moller DR, et al.; ACCESS Research Group. Variation in the lymphotoxinalpha/ tumor necrosis factor locus modifies risk of erythema nodosum in sarcoidosis. J Invest Dermatol 2009;129(8):1921–26.


17. Amoli MM, Llorca J, Gomez-Gigirey A, et al. E–selectin polymorphism in erythema nodosum secondary to sarcoidosis. Clin Exp Rheumatol 2004;22:230–32.


18. Hamblin AS, Shakoor Z, Kapahi P, Haskard D. Circulating adhesion molecules in sarcoidosis. Clin Exp Immunol 1994;96(2):335–38.


19. Berlin M, Lundahl J, Skild CM, et al. The lymphocytic alveolitis in sarcoidosis is associated with increased amounts of soluble and cellbound adhesion molecules in bronchoalveolar lavage fluid and serum. J Intern Med 1998; 244(4):333–40.


20. Judson MA, Baughman RP, Thompson BW, et al.; ACCESS Research Group. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis 2003;20(3):204–11.


21. Okamoto H, Mizuno K, Ohtoshi E. Cutaneous sarcoidosis with cardiac involvement. Eur J Dermatol 1999;9(6):466–69.


22. Suga Y, Ogawa H. Sarcoidosis of the skin. J Journ Clin Med 1994;52(6):1603–07.


23. Mert A, Ozaras R, Tabak F, et al. Erythema nodosum: an experience of 10 years. Scand J Infect Dis 2004;36(6–7):424–27.


24. Bohn S, Buchner S, Itin P. Erythema nodosum: 112 cases. Epidemiology, clinical aspects and histopathology. Schweiz Med Wochenschr 1997;127(27–28):1168–76.


25. Lin JT, Chen PM, Huang DF, et al. Erythema nodosum associated with carcinoid tumour. Clin Exp Dermatol 2004;29(4):426–27.


26. Тареев Е.М., Корнев Б.М., Моисеев С.В. Узловатая эритема в клинике внутренних болезней // Тер. архив 1986. № 6. С. 36–39.


27. Atanes A, Gomez N, Aspe B, et al. Erythema nodosum: a study of 160 cases. Med Clin (Barc) 1991;96:169–72.


28. Requena L, Yus ES. Erythema nodosum. Dermatol Clin 2008;26(4):425–38.


29. Mana J, Marcoval J, Graells J, et al. Cutaneous involvement in sarcoidosis. Relationship to systemic disease. Arch Dermatol 1997; 133:882–28.


30. Katta R. Cutaneous sarcoidosis. A dermatologic masquerader. Am Fam Physician 2002; 65:1581–84.


31. Yanardag H, Pamuk ON, Pamuk GE. Lupus pernio in sarcoidosis: clinical features and treatment outcomes of 14 patients. J Clin Rheumatol 2003;9(2):72–6.


32. Spicknall K, English JC 3rd, Elston DM. Lupus pernio. Cutis 2007;79(4):289–90.


33. Rosenberg B. Ichthyosiform sarcoisis. Dermatol Online J 2005;11(4):15.


34. Sorabjee JS, Garje R. Reactivation of old scars: inevitably sarcoid. Postgrad Med J 2005;81(951):60–1.


35. Antonovich DD, Callen JP. Development of sarcoidosis in cosmetic tattoos. Arch Dermatol 2005;141(7):869–72.


36. Katta R, Nelson B, Chen D, Roenigk H. Sarcoidosis of the scalp: a case series and review of the literature. J Am Acad Dermatol 2000; 42:690–92.


37. Albertini JG, Tyler W, Miller OF. Ulcerative sarcoidosis. Case report and review of the literature. Arch Dermatol 1997;133:215–19.


38. Tada Y, Kanda N, Ohnishi T, Watanabe S. Atypical cutaneous sarcoidosis with diffuse, indurated erythema. Eur J Dermatol 2009; 19(6):639.


39. Heinemann B. Uveitis with Brocq-Pautrier angiolupoid (Boeck disease of the skin). Klin Monbl Augenheilkd 1990;196(5):415–16.


40. Marcoval J, Moreno A, Mai J, Peyri J. Subcutaneous sarcoidosis. Dermatol Clin 2008;26(4):553–56.


41. Bosnic D, Baresic M, Bagatin D, Ilic I. Subcutaneous sarcoidosis of the face. Intern Med 2010;49(6):589–92.


42. Marcoval J, Maia J, Moreno A, Peyri J. Subcutaneous sarcoidosis сlinicopathological study of 10 cases. Br J Dermatol 2005;153(4):790–94.


43. Resnik KS. Subcutaneous sarcoidosis histopathologically manifested as fibrosing granulomatous panniculitis. J Am Acad Dermatol 2006;55(5):918–19.


44. Zic JA, Horowitz DH, Arzubiaga C, King LE. Treatmentof cutaneous sarcoidosis with chloroquine. Review of the literature. Arch Dermatol 1991;127:1034–40.


45. Lee JB, Koblenzer PS. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. J Am Acad Dermatol 1998;39(5 pt 2):835–38.


46. Webster GF, Razsi LK, Sanchez M, Shupack JL. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J Am Acad Dermatol 1991;24:451–54.


47. Ramos-Casals M, Brito-Zeron P, Muooz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007;86(4):242–51.


48. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:70–4.


49. Roberts SD, Wilkes DS, Burgett RA, Knox KS. Refractory sarcoidosis responding to infliximab. Chest 2003;124(5):2028–31.


50. Denys BG, Bogaerts Y, Coenegrachts KL, De Vriese AS. Steroid-resistant sarcoidosis: is antagonism of TNF-alpha the answer? Clin Sci (Lond) 2007;112(5):281–89.


51. Thielen AM, Barde C, Saurat JH, Laffitte E. Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNFalpha antagonists. Dermatology 2009; 219(1):59–62.


52. Cliff S, Felix RH, Singh L, Harland CC. The successful treatment of lupus pernio with the flashlamp pulsed dye laser. J Cutan Laser Ther 1999;1(1):49–52.


53. Patterson C. Successful treatment of cutaneous sarcoid by photodynamic therapy with minimal discomfort using a fractionated dosing regime. Photodermatol Photoimmunol Photomed 2009;25(5):276–77.


Похожие статьи


Бионика Медиа